Abstract The purpose of this study was to quantify the impact of Staphylococcus haemolyticus in the epidemiology of the blood stream infection (BSI) and to characterize the rates and quantitative levels of resistance to antistaphylococcal drugs. During an eight-year period, 2967 BSIs of the patients hospitalized in different clinical departments of the Semmelweis University, Budapest, Hungary were analyzed. One hundred eighty-four were caused by S. haemolyticus, amounting to 6% of all infections. The antibacterial resistance of S. haemolyticus isolates was investigated by the broth microdilution method, vancomycin agar screen, population analysis profile and PCR for mecA, vanA and vanB genes detection. Epidemiological investigation was processed by determining phenotypic antibiotic resistance patterns and PFGE profiles. Extremely high MIC levels of resistance were obtained to oxacillin, erythromycin, clindamycin, gentamicin and ciprofloxacin. The incidence of teicoplanin reduced susceptibility revealed 32% without possessing either the vanA or vanB gene by the strains. PFGE revealed 56 well-defined genotypes indicating no clonal relationship of the strains. The propensity of S. haemolyticus to acquire resistance and its pathogenic potential in immunocompromised patients, especially among preterm neonates, emphasise the importance of species level identification of coagulase-negative staphylococci and routinely determine the MIC of proper antibacterial agents for these isolates.
Introduction
Bacterial bloodstream infections (BSIs) are a major cause of morbidity and mortality. The frequency of these infections, their epidemiology and the invading organisms have changed with the emergence of an increasingly ill, immune-compromised population of hospitalized patients and with using more medical support and indwelling devices.
The greater role of Gram-positive cocci as causative agents of nosocomial BSIs was highlighted by many huge studies from all over the world. Together with Staphylococcus aureus, the coagulase-negative staphylococci (CoNS) were the most frequent bacterial bloodstream isolates analysing the data of different surveillances [1] [2] [3] [4] [5] [6] . However, their role as a real cause of morbidity and mortality is difficult to ascertain. BSIs caused by CoNS do not result in excess mortality, but they lead to both increased rates of morbidity and longer hospitalization and higher overall cost of treatment. Several studies have shown Staphylococcus epidermidis to be the dominant species among CoNS isolated from human blood cultures, and Staphylococcus haemolyticus takes second place [5] [6] [7] [8] [9] [10] [11] [12] . In addition, a large proportion of nosocomial CoNS isolates from patients treated in intensive care units has proven to be resistant to a number of antibiotics, including penicillinase-stable penicillins [12] [13] [14] [15] [16] . Therefore, cyclic glycopeptides (vancomycin and teicoplanin) have been recommended as first empirical therapeutic agents for such serious staphylococcal infections. Moreover, being a potential pathogen, S. haemolyticus can also serve as a donor of resistance genes to the more virulent staphylococcal species such as S. aureus. S. haemolyticus was the first Gram-positive pathogen to acquire glycopeptide resistance [17] [18] [19] , earlier than any other Staphylococcus and Enterococcus species, and has been suggested to be unique among CoNS being predisposed to develop glycopeptide resistance. In a recent investigation Takeuchi et al. [20] analyzed the complete genome sequence of multidrug-resistant strains of S. haemolyticus, demonstrating that it contains 82 IS127. IS elements seem to contribute to the ability of these microorganisms to acquire drug resistance. Recently many studies have analyzed the possible virulence factors of S. haemolyticus, especially biofilm-production [21, 22] , as an early study showed S. haemolyticus strains to produce compact colonies in soft agar and to possess peculiar hydrophobic cell surfaces [23] .
We recently observed a notable number of S. haemolyticus strains causing colonisation and severe infections in the patients of the Intensive Care Units (ICUs) of the Semmelweis University Hospitals. Especially worrisome has been the increased number of S. haemolyticus strains with reduced susceptibility to teicoplanin among bloodstream isolates from newborns treated at the neonatal intensive care units.
The aims of our study were (i) to quantify the impact of S. haemolyticus in the epidemiology of the BSIs among patients treated at the University Hospitals of the Semmelweis University between 2001 and 2008, (ii) to determine the rates and quantitative levels of resistance of S. haemolyticus strains to antistaphylococcal drugs, (iii) to reveal epidemic phenotypic antibiotic resistance patterns, and (iv) to examine correlations between PFGE genotypes and phenotypic resistance patterns.
Material and methods

Sources of strains
During the years 2001-2008 a total of 2,967 BSIs of the patients hospitalized in different departments of the Semmelweis University, Budapest, Hungary were analyzed on the basis of blood culture results. Because the interpretation of a CoNS blood culture isolate as a pathogen or contaminant is problematic, relatively stringent criteria were used to determine their etiologic role. Isolates from blood cultures were judged to be involved in the infection if they represented the only microorganism isolated from the blood in the presence of clinical signs or symptoms of sepsis. Among adult patients the isolation of the same CoNS species with a similar biotype and antimicrobial susceptibility profile from at least two blood cultures were regarded as evidence of true BSI. Only the first invasive isolate per patient was considered in this study. Since the neonatologists obtained only a single blood culture from an infant with suspected sepsis in more than 70% of the cases, a positive cultivation result from blood culture of these patients was always verified by a clinician.
Taxonomic identification of strains
S. haemolyticus strains were identified by the VITEK system (bioMérieux, Lyon, France) according to the manufacturer's instructions. They were stored at −80°C with 25% glycerol for subsequent phenotypic and genotypic examinations.
MIC determination
Quantitative antibiotic resistance levels of the strains were measured by determining the minimal inhibitory concentrations (MICs) of oxacillin, vancomycin, teicoplanin, erythromycin, clindamycin, gentamicin, sulfamethoxazoletrimethoprim, doxycycline, ciprofloxacin, and linezolid with the reference broth microdilution method in cation supplemented Mueller-Hinton broth using break points according to guidelines of NCCLS earlier and those of later Clinical Laboratory Standards Institute (CLSI) [24] .
Determination of antibiotic resistance pattern
Resistance phenotypes of the S. haemolyticus strains were defined through a value representing the number of antibiotics to which the strain was resistant to any of the following: oxacillin, erythromycin, clindamycin, gentamicin, sulfamethoxazole-trimethoprim, doxycycline and ciprofloxacin, as well as with a letter subscript indicating the particular combination of antibiotics to which the isolate was resistant. Isolates showing an intermediate sensitivity were classified as resistant. Non-sensitivity to glycopeptides was not considered in this differentiation because determination of their efficiency requires more special investigation methods. Multidrug resistance was defined as resistance to oxacillin and at least to two antibiotic classes other than β-lactams.
Investigation of resistance to glycopeptides Beside the determination of MIC level of vancomycin and teicoplanin, vancomycin screen agar were also used according to the CLSI guidelines [24] . Modified population analysis profiles (PAPs) were also done [25] to determine heteroresistance to vancomycin among S. haemolyticus strains. Every test sample run was accompanied by using the Mu3 and ATCC 29213 S. aureus strains as controls. A ratio was then calculated by dividing the area under curve (AUC) of the test strain by the AUC of Mu3. PAP-AUC criteria for the determination of vancomycin resistance, glycopeptide-intermediate Staphylococcus spp. (GIS) and the hetero-GIS (hGIS) are as previously described and are based on multiple tests with Mu3 ≤0.9 as methicillinresistant Staphylococcus spp, 0.9-1.3 as hGIS, and ≥1.3 as GIS [26] .
Amplification of methicillin resistance gene (mecA)
Methicillin resistance was confirmed by showing the presence of mecA gene in the strains with the PCR method [27] . Amplifications were performed in a Progene Techne thermocycler (Techne).
Detection of glycopeptides resistance genes
Because a good number of S. haemolyticus strains showed reduced susceptibility to teicoplanin, vanA and vanB were searched in the strains by the method described by DutkaMalen et al. [28] .
Determination of clonality of the strains by pulsed-field gel electrophoresis (PFGE) PFGE was executed by an internal protocol modified for CoNS [29] . S. haemolyticus strains were grown overnight on blood agar plates at 37°C, and DNA was released from the cells by using lysostaphin-lysis (Sigma). DNA was digested with SmaI (Promega, Madison, WI, USA) at 25°C for 3 h. PFGE was performed in 1% agarose gel (Bio-Rad) using a CHEF-DR-II apparatus (Bio-Rad) in TBE buffer (1X Tris-borate-EDTA, pH:8.3; Bio-Rad). Lambda DNA PFGE Marker (BioLabs, Budapest, Hungary) was used as size standards in the first lane on each gel. Electrophoresis conditions were 14°C for 21 h, with pulse time ranging from 5 to 60 sec at an angle of 120°; voltage was 6 V/cm. Gels were stained with a solution of ethidium bromide (Sigma) and digitalized with UVItec (Pharmatia Biotech) equipment. The DNA band patterns obtained were analyzed visually and with the aid of Diversity Database software, version 2.2.0 (Bio-Rad). Dendrograms were created using UPGMA clustering of a similarity matrix based on bandmatching Dice coefficients (tolerance 1%, optimization 1%). Isolates showing indistinguishable or closely related band patterns (≤6 band differences, >8% similarity) were regarded as possibly clonally related as suggested by Tenover et al. [30] .
Results
Frequency of S. haemolyticus in bloodstream infections
According to Table 1 the vast majority of BSIs were caused by Gram-positive microorganisms during the examination period (41-68%). S. haemolyticus caused approximately 6% of all infections and 11% of all the Gram-positive episodes. Overall 184 BSIs were caused by S. haemolyticus in patients with clinical signs of sepsis treated at different hospital wards of the Semmelweis University. S. haemolyticus was the second most common cause of CoNS bacteremia (after S. epidermidis) and ranging between 12% and 26% of all CoNS isolates in different years. However, considerable differences were observed when the distribution of S. haemolyticus isolates was compared according to different departments (Table 2 ). In patients treated in the two independent Neonatal Intensive Care Units (NICU) almost 18% and 15% of the bloodstream isolates were S. haemolyticus, while 4 % of the BSI isolates were S. haemolyticus from the patients of the "adult" intensive care units. Surgical departments were characterised by 5-6% S. haemolyticus BSI, whereas 0-3% of the bloodstream isolates from internal medicine or other patient wards belonged to this species.
Antibacterial sensitivity patterns of isolates
Of the S. haemolyticus isolates 97% exhibited phenotypical oxacillin resistance. PCR amplification showed the presence of the mecA gene in each of these strains. The resistance to erythromycin, clindamycin, gentamicin, sulfamethoxazole/trimethoprim and ciprofloxacin was 96%, 62%, 87%, 49%, and 84%, respectively, with evenly high MIC levels during the investigation period (Table 3) . No inducible MLSB phenotype was found among erythromycin resistant and clindamycin sensitive strains. Every strain was sensitive to linezolid and the resistance rate to doxycycline was surprisingly low (15%). All of the isolates were vancomycin-sensitive according to the criteria of the CLSI, but 32% of them had a vancomycin MIC of 2 μg/ml. None of the strains formed resistant colonies on 6 μg vancomycin per ml agar plate under the special incubation conditions. None of the strains showed heteroresistance to vancomycin at 1 μg/ml determined by the modified population analysis profiles, but among the strains which showed 2 μg/ml vancomycin MIC, 45% were hGIS and 36% GIS. MICs of teicoplanin were 1-8 μg/ml (susceptible) for 68% of the strains; 16 μg/ml (intermediate) for 18% of the strains; and 32 μg/ml (resistant) for the remaining 14% of the strains. None of teicoplanin-resistant strains contained vanA or vanB genes investigated by PCR. 
Antibiotic resistance patterns
In an attempt to use the phenotypical antibiotic resistance profile as an epidemiological marker, we defined resistance phenotypes through a number and a letter as described in Materials and Methods. Altogether 33 distinct resistance phenotypes were found, 96% of the isolates showed multiresistance. Among them, as Table 4 shows, six phenotypes were considered as epidemic patterns amounting to 78% of all S. haemolyticus strains. Occurrences of other resistance patterns were under 1% (data not shown). Our analysis revealed that 5% of all the strains were resistant to all antibacterial agents except glycopeptides and linezolid. Twenty-five percent of the strains were resistant to six antimicrobial agents, 39% to five, 22% to four, 5% to three and just 3% of the strains to none or two different antimicrobial agents. Many strains showing the same antibiotic resistance pattern were isolated from different, structurally non-connected wards of the university hospital wards, while many with different antibiotic resistance patterns were identified from the same ward (data not shown).
Clonal relationship of the strains
The PFGE patterns were characterised by 12-19 bands ranging from 40 to 600 kb. Fifty-six well-defined profiles of genomic DNA after SmaI digestion were obtained from 184 S. haemolyticus strains. According to the criteria of Tenover et al. [30] , 27 PFGE types and 29 subtypes were found. These 29 subtypes were associated with 11 types of the 27 main types. Twenty-seven types displayed similarity coefficients from 25-80%; each was coded with a number. Each subtype was coded with a letter (similarity≥80%). Figure 1 exhibits the dendrogram resulting from the computer-assisted analysis of the PFGE profiles of all 56 distinct pattern types. It proves the genetic heterogeneity of the strains after SmaI digestion. Many strains showing the same PFGE type or subtype were isolated from patients treated in different, structurally non-connected wards of the university hospital, while many different PFGE types or subtypes were identified from patients in the same ward. There was no correlation between antibiotic resistance phenotypes and PFGE genotypes.
Discussion
Our data clearly show the increasing importance of Grampositive cocci among bloodstream isolates during recent years, as this re-emergence has been found in other publications as well [1, 2, 4, 31, 32] . Of them, S. haemolyticus strains constituted 6% of all bloodstream isolates in our study and appeared to be more prevalent in Oxacillin  90  100  96  96  100  92  93  100  97  4 to>256  >256  >256  Erythromycin  100  95  96  100  100  92  87  94  96  1 to>256  128  >256  Clindamycin  70  82  66  65  45  50  47  76  62  2 to>256  >256  >256  Gentamicin  80  91  89  85  89  75  87  94  87  2 to>256  128  >256  Sulph./trimethoprim  50  41  36  50  47  83  67  53  49  4 to >256  128  >256  Doxycycline  70  27  9  15  8  8  20  0  15  2-32  2  8  Ciprofloxacin  50  73  84  88  97  83  80  88  84  <0.5 to >256  64  128  Levofloxacin  50  73  83  88  97  83  80  88  81  <0.5-64  16  32  Moxifloxacin  50  73  82  88  95  83  80  88 
Values given as %, except for MICs 100  95  90  85  80  75  70  65  60  55  50  45  40  35  30  25  20  15  10  5  0  136   145   44 intensive care units, especially in those for neonates, than in the other departments. Our data harmonize with results of many studies from all over the world [4-8, 12, 19, 33] , when authors indicated that S. haemolyticus accounted for 5-38% of all CoNS clinical isolates. The unique specificity reflects the fact that some patients, e.g. critically ill ones receiving many invasive therapeutic interventions in ICUs, have a higher risk of becoming colonized or infected. Especially premature newborns are at the highest risk for S. haemolyticus infections. The vast majority of the S. haemolyticus strains in our collection were multidrug-resistant. However, the multiple resistances in these S. haemolyticus strains were proved not to be uniform. Several phenotypical resistance patterns were found with four relatively frequent types characterized by a simultaneous resistance to oxacillin, erythromycin, gentamicin, and ciprofloxacin. It is clinically important that 97% of BSI isolates contained the mecA gene, resulting in a very high level of oxacillin and consequently β-lactam resistance, which is unusual in the literature [7, 9, 14] . Our other alarming finding is the 14% teicoplanin resistance with 4 μg/ml MIC 50 and 32 μg/ml MIC 90 . This means that teicoplanin cannot be considered any longer as a first line drug against S. haemolyticus infection in this country. Our results support the suggestion that vancomycin remains the only available agent that is still active in both empirical and susceptibility testing based treatment of severe infections caused by methicillin-teicoplanin-resistant S. haemolyticus. With our screening method none of the S. haemolyticus isolates proved to be resistant to vancomycin using CLSI criteria, but 32% of them had an MIC of 2 μg/ml for vancomycin.
The problem is more serious if we reanalyse our results using recent EUCAST guidelines (www.eucast.org) for the determination of glycopeptide resistance. Thirty-seven percent of all S. haemolyticus strains were resistant to teicoplanin (MIC >4 μg/ml) according to EUCAST guidelines. Added to this, our results also show that the heteroresistance to vancomycin investigated by the modified population profile analysis is high. Among the sensitive strains (with MIC of 2 μg/ml) the occurrence of strictly sensitive strains (PAP AUC <0.9) was just 19%. Recently, several reports have focused on the emergence of vancomycin-resistant S. haemolyticus isolates, which have shown a stepwise increase in vancomycin therapy, but the true clinical significance of this phenomenon is not clear [12, 18, 19, [34] [35] [36] [37] .
Our data indicate that doxycycline and linezolid may be effective against some of the multidrug-resistant S. haemolyticus strains and also used for empiric therapy beside vancomycin, but the clinical significance of these findings should be investigated further in the future.
The PFGE analysis of our clinical isolates of S. haemolyticus from blood cultures revealed heterogeneous PFGE patterns with no predominant genotype. This fact indicates that we examined many genotypically different strains, not subcultures of the same strain, thus our conclusions are valid for the S. haemolyticus species itself. Our results also confirm other reports with regard to the large genomic variability presented by S. haemolyticus [38, 39] . Some studies revealed typically high genetic homogeneity if the isolates were "outbreak-strains" from the same unit of the hospital [31] . Our strains showed no correlation between the phenotypical antibiotic resistance patterns and PFGE genotypes. Because of these data and the multiresistance of S. haemolyticus, the antibiotic resistance patterns are not useful for epidemiological investigation and characterization.
It is absolutely clear that surveillance programmes are necessary to identify changes in the spectrum of microbial pathogens causing serious infections and to monitor trends in antimicrobial resistance patterns in both nosocomial and community-acquired infections [9, 30, 40] . Since S. haemolyticus seems to be a unique species among CoNS, it is mandatory to identify CoNS isolates causing BSI to species level. However, a large number of studies failed to do so [12, 41] . Species identification of CoNS would have clinical and epidemiological interest for the clinicians. This situation is similar to what we found in fungal infections, namely, Candida krusei means fluconasole-resistance, and S. haemolyticus means oxacillin-and very probably teicoplanin-resistance. In addition, multi-resistant S. haemolyticus, as a potential pathogen and a resident member of normal bacterial flora of the skin, may also serve as a donor of resistance genes to other species, particularly to the more virulent S. aureus [42] [43] [44] . Thus intra-and interspecies transfer of resistance genes should be seriously considered. This is the first survey on the S. haemolyticus species from Hungary and its teicoplanin resistance. The propensity of S. haemolyticus to acquire resistance and its pathogenic potential in immunocompromised patients emphasise the importance of species level identification of CoNS and to routinely determine the MIC of proper antibacterial agents for these isolates and then investigate the epidemiology. Further studies are required to evaluate the significance of different virulence and host factors contributing to the pathogenesis of S. haemolyticus sepsis.
